# ROSELLA / GOG-3073

Source: https://onco.cc/trials/rosella/  
OnCo record `rosella` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Blocking cortisol signalling in tumour cells made chemotherapy work better and extended life in resistant ovarian cancer.

## Summary

ROSELLA, also GOG-3073, trial NCT05257408 sponsored by Corcept and published in the Lancet in 2025, showed that blocking cortisol signalling in tumour cells with relacorilant makes nab-paclitaxel chemotherapy work better and extends life in platinum-resistant ovarian cancer. It randomised 381 women with one to three prior lines to relacorilant plus nab-paclitaxel or nab-paclitaxel alone, met its primary progression-free survival endpoint and improved overall survival, leading to FDA approval in the first quarter of 2026 as Lifyorli, the first-in-class glucocorticoid receptor antagonist in oncology. OnCo links it to ovarian cancer, relacorilant, paclitaxel and Corcept Therapeutics, and the record notes it as a chemosensitisation mechanism rather than a new cytotoxic. Whether the approach transfers to other chemotherapy-treated cancers is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT05257408
- Phase: 3
- Setting: Platinum-resistant ovarian cancer, 1-3 prior lines: relacorilant + nab-paclitaxel vs nab-paclitaxel
- Sponsor: Corcept
- Enrolled: 381
- Result: OS 16.0 vs 11.9 months (HR 0.69).
- Outcomes: Progression-free survival: Relacorilant + nab-paclitaxel 6.5 months vs Nab-paclitaxel 5.5 months, HR 0.7; Overall survival: Relacorilant + nab-paclitaxel 16 months vs Nab-paclitaxel 11.9 months, HR 0.69

## Sources

- ClinicalTrials.gov NCT05257408: https://clinicaltrials.gov/study/NCT05257408

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Relacorilant](https://onco.cc/drugs/relacorilant/)
- companies: [Corcept Therapeutics](https://onco.cc/companies/corcept/)
- key papers: [ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer](https://onco.cc/key-papers/paper-rosella-relacorilant-lancet-2025/)

---
JSON: https://onco.cc/api/v1/entities/rosella.json